TScan Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 30 →Insiders2 insiders bought $145,621 in 3 open-market buys. No sales.→HoldersLynx1 $7.9MBVF Inc/il $5.5MBaker Bros $2.7M→PeersClosest companies: FATE, JANX, ACET→
From the filings
Figures
- Revenue
- $7.1Mlast 12 months
- Net income
- −$117.7Mlast 12 months
- Operating cash flow
- −$122.0Mlast 12 months
- Cash and equivalents
- $100.2Mat the last balance sheet
- Total debt
- $32.8Mat the last balance sheet